Clinical Trial

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US
Trial Details
NCT Number NCT07024862
Lead Sponsor Bristol-Myers Squibb
Conditions Metastatic Non-small Cell Lung Cancer
Enrollment 100 participants
Start Date 2024-10-24
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-17